CA1283051C - Porous bioabsorbable polyesters - Google Patents
Porous bioabsorbable polyestersInfo
- Publication number
- CA1283051C CA1283051C CA000523151A CA523151A CA1283051C CA 1283051 C CA1283051 C CA 1283051C CA 000523151 A CA000523151 A CA 000523151A CA 523151 A CA523151 A CA 523151A CA 1283051 C CA1283051 C CA 1283051C
- Authority
- CA
- Canada
- Prior art keywords
- polyether
- article
- polylactone
- porous
- shaped
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0092—Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7007—Drug-containing films, membranes or sheets
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/13—Hollow or container type article [e.g., tube, vase, etc.]
Abstract
Porous Bioabsorbable Polyesters Abstract Polylactones blended with a polyether and then shaped are leached with aqueous solution of an organic solvent such as alcohol or acetone to elute selectively the polyether and form interconnected pores within the shaped polylactone. The result is a shaped article suitable for use as a reservoir for the controlled release of high molecular weight drugs.
Description
33~1 Porous Bioabsorbable Polyesters Backqround Art The present invention relates to bioabsorbable polyesters possessing porous structures and their use in novel polymer-drug formulations. More specifically, this invention relates to the fabrication of tubular drug delivery devices from polycaprolactone or its copolymers with other lactones, said devices possessing walls of defined porosities which can be adjusted by proper selection of the production parameters to yield formulations exhibiting the desired rates of drug release~
U.S. Patent NoO 3,887,699 to Yolles discloses a device for dispersing drugs from a biodegradable polymeric material which is shown to be polylactate.
U.S. Pa~. NoO ~148,871 to Pitt, et al, discloses the use of biodegradable homopolymers and copolymers of -caprolactone for formulating devices to accomplish the sustained subdermal delivery of drugs. Neither of these references, however, discloses the use or the fabrication of bioabsorbable devices, exhibiting a ! porous polymer structure. As a consequence of the dense structure of the polymeric component of the disclosed polymer-drug formulations, the application of i these devices is limited to drugs of low molecular weight (less than 500 dalton) which in addition must be sufficiently soluble in the encapsulating polymer. In contrast to both the disclosed dru~ delivery devices, the novel polymer-drug formulations of the present invention utilize porous polymers and, consequently, -. .
~283~
the applications of these novel devices are not restricted by themolecular weight of the dispensed drug or its solubility in the polymer.
U.S. Pat. Nos. 4,045,41~ and 4,057,537 to Sinclair disclose the fabrications of random copolymers of ~-caprolactone with D,L-lactide and L-lactide, respectively. These patents do not, however, disclose the concept of polymer-drug formulations of the controlled delivery of drugs.
The fabrication of porous polylactate and porous polylactate-polyurethane blends and the use of these materials for biodegradable prosthetic devices have been disclosed in several scientific publications. See for example S. Gogolewski and A.J. Pennings, Makromol. Chem., Rapid. Comm., 3, 839 (1982), 4, 213 (1983); Coll. Polym. Scio~ 261, 477 (1983). The disclosures by Gogolewski and Pennings do not include the concept of the controlled release of high molecular weight drugs which is germane to the present invention and are restricted to polylactate and its blends with polyurethanes.
Disclosure of the Invention The controlled release of high molecular weight drugs from polymeric reservoir devices requires porous reservoir walls, especially for drugs which are hydrophilic and practically insoluble in the hydrophobic polymer. The pores in the reservoir walls ~, ..
~Z830~;1 have to be interconnected to provide a continuous path for the migrating drug which then diffuses from the reservoir at a rate governed by the tortuosity of the diffusion path.
In accordance with the present invention, tubular devices possessing porous tube walls can be fabricated from polycaprolactone or its copolymers, as well as polyvalerolactone and its copolymers (e.g~ with lactic acid~ containing an additive which is selectively removed by treatment with appropriate solvents.
Suitable polymers or copolymers have an average molecular weight ranging from about 40,000 to about 250,000 or higher. If the molecular weight is too low, the structure of the device may be too weak and tend to degrade. A preferred average molecular weight is about 100,000.
~', , .
Pore forming additives of lnterest are low molecular weight aliphatic polyethers which are commercially available (Pluronics, BASF Wyandotte) so that neither the compounds per se nor the method by which they are obtained constitutes any portion of this invention. Among the different available grades of polyethers~pLuRoNIc* F-68 is of particular interest because it has found FDA approval for medical applications. Residues of this polyether remaining in the porous tube walls after the pore-forming process can be tolerated and, indeed, are beneficial for the release performance of the devices by increasin~ the wettability of the pore surfaces. Appropriate solvents for selectively removing the incorporated polyether from polycaprolactone or its copolymers during the pore-forming process are aqueous sol~tions of organic i * Trade mark ,~ '~. .
, . -::
,.
' ' ' ' .
, ~ .
~ ~2~3()~i'1 solvents at concentrations at which dissolution of the polycaprolactone or its copolymers does not take place. UseEul solvents for the selective elution of the polyether are among others aqueous solutions of methanol, ethanol, or acetone.
The formation of interconnected pores is demonstrated by the water uptake of the porous polymers. A sample o~ the porous polymer of known weight is kept submerged in water and the vessel containing the submer~ed sample is evacuated until gas evolution ceases. Then air is admitted and the sample is weighed after removal of adherent water droplets.
The fractional void content, fv~ is then calculated from fv = (wl + ~2)/W2 where wl and w2 are the weights of the sample in the dry and wet states, respectively.
Unexpectedly, it was found that the formation of interconnected pores by selective leaching of the pore-forming polyether occurs only inside a narrow temperature range of about 40~55C~ preferably about 40-45~C. More specifically, it was found that the leachin~ temperature and the composition of the eluant play a dominant role which determines the void content and the average pore dimensions of the porous tube walls. This unexpected result which assigns a lesser importance to the initial polyether content is demonstrated by the data of Table 1 which reveal that the void content of the porous polycaprolactone can considerably exceed the volume fraction of the initially present polyether. Indeed, void contents exceeding 60~ can he obtained with polycaprolactone initially containing only 5 wt-% of the polyether `'`
In ~eneral the void content increases with the content of the organic component in the aqueous eluant. There exists a critical concentration for the organic component below which the void content remains low despite all of the added polyether being eluted.
For agueous solutions of acetone this critical concentration is around 45 vol-% acetone at 40C
elution temperature and decreases to about 25 vol-%
acetone at 45C. Above the critical concentration partial melting and recrystallization of the polycaprolactone takes place during the leaching process which results in a pore structure composed of interconnected pores. Below the critical concentration the porous structure of the leached polycaprolactone changes to one of low void content and being composed of closed cells.
Table 1. Ef~ect of Leaching Conditions on the Void Content of the Walls of Porous Polycaprolactone Tubes .
Vol.-~ Percent Void Content at Acetone 40C 45C
Initial F-68 Content: 5 wt-~
5.0 5.8 6.2 15.0 15.7 35~5 45.9 59.3 66.5 75.7 Initial F-68 Content: 15 wt-%
10 6.9 9.
20 7.5 6.8 . .
'Z~330~;~
8.1 42.4 9.5 65.7 55.9 78.4 77.1 80.1 Initial F-68 Content~ 25 wt-~
6.~ 6.9 6.8 9.7 7.7 71.5 10.2 73.1 66.8 76.9 82~7 83.3 Broadly stated, the present invention provides an article suitable for use as a controlled release reservoir for high molecular weight drugs, comprising a porous polymer formed by:
~13 shaping a polylactone in the presence of a polyether; and ~2) selectively eluting said polyether at a temperature of about 40~C to 55C from sai.d ~; shaped polylactone to form interconnected pores therein.
The invention additionally provides methods for making such an article.
Brief Description of the Drawin~s The FIGURE is a graph which illustrates the cumulative release of decapeptide descrlbed in Example 1 .
3L283~
Best Mode for CarrYing Out the Invention The preparation of formulations in which the drug is contained within the cavity of the polymeric device of the present invention is a three step process. The first step involves the preparation of the tubular, non-porous, and drug-free polymeric device suitable for the subsequent pore-forming process. This is accomplished by conventional methods such as extrusion, injection molding, dip casting, or annealing of rolled films utilizing intimate blends composed of polycaprolactone or a suitable copolymer of caprolactone and proper amounts of a polyether such as Pluronic F-68. Intimate blends of polycaprolactone or its copolymers with the pore-forming polyether can also be prepared in situ by polymerizing the corresponding lactones in the presence of the polyether which has to be endcapped by acetyl groups. The amount of polyether such as Pluronic F-68 or its endcapped modification can be in the range of 5-S0~ ~w~w) but i~ preferentially between 10-25% (w~w).
During the second process step the tube walls are made porous by selectively removing the pore-forming additive in a leaching process utilizing aqueous solutions of an organic solvent such a~ methanol, ethanol, or acetone. The concentration of the organic component of the leaching bath can be in the range of lO-lO0~ (vJv). The proper selection of the concentration to be utilized depends on the kind of the organic component in the leaching solution, the temperature of the leaching path, the initial polyether eontent of the polylactone, and the desired porosity to be obtained in the final product.
330~
The leaching process must be performed at an elevated temperature between about 40 and 55~C in order to obtain porous tube walls with interconnected pores. During the leaching process the polymer tubes are supported by inserted stainless steel rods and the bath is mildly agitated. Selective elution of the pore-forming additive is generally complete after 2-3 hours when the porous tubes are cooled with ice water to facilitate crystallization. The tubes are then washed with deionized water at ambient temperature, and dried under vacuum at ambient temperature.
In the third step of the process, after fabrication of the structure, a desired drug is introduced into the cavity of such devices in a suitable form, e.g. as micronized powder or in form of a mixture with a suitable solvent, diluent, or dispersing agentO As is well documented in the public literature, and as is well known to those skilled in the art, the amount of drug, the dimensions of the polymeric device, and the amount of solvent, diluent or dispersing agent, may be varied such that th~ rate of drug delivery and the time over which the drug is delivered are considered optimum for the particular therapeutic application. The device of the present invention is in the form of a cylindrical tube with the drug contained within the interior cavity formed by the porous walls and both ends of the tubular device being closed by heat sealing.
The rate at which the polymeric device is degraded within the body is determined by the chemical structure and the molecular weight selected for the fabrication of the device as well as the mode of administration to the patient~ Polycaprolactone with an intrinsic ~13305~1L
_9 viscosity in toluene of greater than one dl/g does not begin to lose significant mechanical strength or weight for at least 12 months. A copolymer of caprolactone and dilactide with the same intrinsic viscosity is degraded within two to three months.
The following examples are offered to more fully illustrate the invention, but are not to be construed as limiting the scope thereof.
A polmer tube of 60 mm length, 2.0 mm inner diameter, and 0.15 mm wall thickness was prepared from a blend composed of 70 parts per weight of polycaprolactone with an intrinsic viscosity of 1.9 dl/g in toluene and 30 parts per weight of Pluronic F-68. After supporting the tube by an inserted stainless steel rod, the Pluronic F-68 was selectively eluted by submerging the tube in a mixture composed of one part ethanol and two parts water at 50C for 8 hours. At the end of the leaching period the tube was chilled with ice water, washed~ and then dried under vacuum at ambient temperature. From tube weight and geometric dimensions a void content of 59% was calculated.
Micrographs obtained by scanning electron microscopy revealed a very open cell structure with interconnected holes in the cell walls of about 6-8 ~m in diameter.
The pores of the wall surfaces were about 20 ~m in diameter and represented about 10% of the tube surface.
A 30 mm length of the prepared porous tube was heat sealed at one end by pressing it under rotation into a fitking conical indentation of a small Teflon block thermostated at 72C. The tube was then filled 33~5~
with 5.8 mg of a synthetic decapeptide followed by 60 mg of water. After heat sealing the tube was immersed in deionized water at 38 (and the release of the decapeptide was monitored by its absorbance at 220 nm. The decapeptide was released with a nearly constant rate of 140 ~g/day for a time period of 33 days when the device was depleted to about 20~ of its initial drug content. The release rate of the decapeptide is graph;cally depicted in the FIGURE.
In a control experiment under identical conditons but utilizing a non-porous polycaprolactone tube of identical dimensions, no release of the decapeptide could be observed during a time period of one month.
The procedure of example 1 was repeated with incorporation of the following changes. The polymer tube was prepared from a blend composed of 60 parts per weight of the polycaprolactone of example 1 and 40 parts per weight of Pluronic F-68. Selective elution of the Pluronic F-68 content was performed with a mixture of two volumes methanol and three volumes water at 50C for 16 hours. The void content of the porous tube walls was found to be 65~.
A porous polymer-drug formulation was prepared by filling a 30 mm length of the prepared porous tube with 4.6 mg of the decapeptide of example 1 and 50 mg of water. The release of the decapeptide into deionized water was monitored as in example 1 for 66 days when the drug content was completely exhausted. The maximum release rate during this time period was found to be :;.
a~o~
158 ~g/day.
A porous polymer tube wa~ prepared according to the procedure of example l but utilizing a methanol-water mixture with a volume ratio of 1:2 for the elution of the Pluronic F-68 content at 50C for lO
hours. A 27 mm length of the resulting porous tube was used for the preparation of a polymer-drug formulaton composed of 13.4 mg of an oligopeptide with a molecular weight of 5000 and 68 mg of water. The release rate of the oligopeptide into deionized water at 38C was monitored for 50 days by its abso~bance at 215 nm and was found to be in the range of 20-60 ~g/cm/day.
A porous tube was prepared according to the procedure of example l but utilizing a polymer blend composed of 80 parts per weight of polycaprolactone and 20 parts per weight of Pluronic F-68. The Pluronic F-68 content was eluted with a methanol-water mixture of a volume ratio of 2:l at 50C for l.3 hours. A porous capsule of 27 mm length was prepared which contained 20 mg of riboflavin dispersed in 60 ~l of water. The release of the riboflavin into deionized water at 38C
was monitored by its absorbance at 444 nm. During the investigated time period of 25 days a release rate of 48 ~g/cm/day was observed. In a control experiment extending over the same time period the total release of riboflavin from a non-porous polycaprolactone capsule of identical dimensions amounted to less than ,.~ lZ83 5 ~g.
The procedure of example 1 was repeated with incorporation of the following changes. The polymer tube was prepared from a blend composed of 23 parts by weight of Pluronic F-68 and 77 parts per weight of a random copolymer of E-caprolactone and ~-valerolactone containing 20 mol-~ of ester groups derived from the latter lactone. Selective elution of the Pluranic F-68 content was performed at 48C in a mixture of equal volumes of methanol and water for 8 hours. The void content of the porous tube wall was found to be 62%.
A 25 mm length of the prepared porous tube was loaded with 5.3 mg of the decapeptide of example 1 and 49 mg of water. The release rate of the decapeptide into deionized water was monitored as in example 1 for 40 days and was found to remain nearly constant at 180 ~g/day.
, A porous tube was prepared according to the procedure of example 1 by utilizing a polymer blend composed of 20 parts per weight of Pluronic F-68 and 80 parts per weight of a random copolymer of ~-caprolactone and L-dilactide containing 15 mol-% of ester groups derived from the dilactide. Selective elution of the Pluronic F-68 content at 52C in a methanol-water mixture of ratio 3:2 for 6 hours yielded a tube with porous walls ~ith a void content of 78~.
A 30 mm length of the prepared porous tube was lZ~33~5~
loaded with 6.2 m~ of the decapeptide of example l followed by 70 mg of water. The monitored release rate of the decapeptide into deionized water was found to be 230 ~g/day.
Pluronic F-68 was endcapped with acetyl groups by dissolving lO0 g F-G8 in lO0 ml freshly distilled pyridine and adding 50 ml freshly distilled acetic anhydride. After refluxing the solution for 6 hours the solvents were removed on a rotary evaporator until solidification. The solid was Soxhlet extracted with pentane for 24 hours and then vacuum dried at 40C for 24 hours.
Fifteen parts per weight of the endcapped polyether were dissolved in 85 parts per weight of caprolactone and 200 ppm of stannous octoate were added as a catalyst. The solution was kept in a sealed container at 120C for 18 hours when the conversion to polymer was better than 98~. The polymer was removed as a melt from which a film of about 0.1 mm thickness was compression molded. The intrinsic viscosity of the polymer in toluene was 0.7 dl/g.
A porous film was prepared by placing the film into an aqueous solution containing 45 vol-% acetone at 45C for 12 hours. The void content of the film as determined by its water uptake was 78~.
~.
A crosslinked polycaprolactone film was prepared by polymerizing between Teflon plates a solution composed of 85 parts per weight of caprolactone, 15 parts per weight of acetyl enclcapped Pluronic F-68 of example 7, 1 part per weight of 2,2-bis(6-hexanolacton-4-yl)propane, and 200 ppm stannous octoate. The polymerization was performed at 120C for 18 hours.
The film was made porous by placing it into an aqueous solution containing 70 vol-~ acetone at 40C
for 12 hours. The void content of the crosslinked film as determined by its water uptake was 88%.
While the invention has been described above with reference to specific examples and embodiments, it will be understood that the invention is not to be ]imited to specific examples and embodiments except as defined in the following claims.
U.S. Patent NoO 3,887,699 to Yolles discloses a device for dispersing drugs from a biodegradable polymeric material which is shown to be polylactate.
U.S. Pa~. NoO ~148,871 to Pitt, et al, discloses the use of biodegradable homopolymers and copolymers of -caprolactone for formulating devices to accomplish the sustained subdermal delivery of drugs. Neither of these references, however, discloses the use or the fabrication of bioabsorbable devices, exhibiting a ! porous polymer structure. As a consequence of the dense structure of the polymeric component of the disclosed polymer-drug formulations, the application of i these devices is limited to drugs of low molecular weight (less than 500 dalton) which in addition must be sufficiently soluble in the encapsulating polymer. In contrast to both the disclosed dru~ delivery devices, the novel polymer-drug formulations of the present invention utilize porous polymers and, consequently, -. .
~283~
the applications of these novel devices are not restricted by themolecular weight of the dispensed drug or its solubility in the polymer.
U.S. Pat. Nos. 4,045,41~ and 4,057,537 to Sinclair disclose the fabrications of random copolymers of ~-caprolactone with D,L-lactide and L-lactide, respectively. These patents do not, however, disclose the concept of polymer-drug formulations of the controlled delivery of drugs.
The fabrication of porous polylactate and porous polylactate-polyurethane blends and the use of these materials for biodegradable prosthetic devices have been disclosed in several scientific publications. See for example S. Gogolewski and A.J. Pennings, Makromol. Chem., Rapid. Comm., 3, 839 (1982), 4, 213 (1983); Coll. Polym. Scio~ 261, 477 (1983). The disclosures by Gogolewski and Pennings do not include the concept of the controlled release of high molecular weight drugs which is germane to the present invention and are restricted to polylactate and its blends with polyurethanes.
Disclosure of the Invention The controlled release of high molecular weight drugs from polymeric reservoir devices requires porous reservoir walls, especially for drugs which are hydrophilic and practically insoluble in the hydrophobic polymer. The pores in the reservoir walls ~, ..
~Z830~;1 have to be interconnected to provide a continuous path for the migrating drug which then diffuses from the reservoir at a rate governed by the tortuosity of the diffusion path.
In accordance with the present invention, tubular devices possessing porous tube walls can be fabricated from polycaprolactone or its copolymers, as well as polyvalerolactone and its copolymers (e.g~ with lactic acid~ containing an additive which is selectively removed by treatment with appropriate solvents.
Suitable polymers or copolymers have an average molecular weight ranging from about 40,000 to about 250,000 or higher. If the molecular weight is too low, the structure of the device may be too weak and tend to degrade. A preferred average molecular weight is about 100,000.
~', , .
Pore forming additives of lnterest are low molecular weight aliphatic polyethers which are commercially available (Pluronics, BASF Wyandotte) so that neither the compounds per se nor the method by which they are obtained constitutes any portion of this invention. Among the different available grades of polyethers~pLuRoNIc* F-68 is of particular interest because it has found FDA approval for medical applications. Residues of this polyether remaining in the porous tube walls after the pore-forming process can be tolerated and, indeed, are beneficial for the release performance of the devices by increasin~ the wettability of the pore surfaces. Appropriate solvents for selectively removing the incorporated polyether from polycaprolactone or its copolymers during the pore-forming process are aqueous sol~tions of organic i * Trade mark ,~ '~. .
, . -::
,.
' ' ' ' .
, ~ .
~ ~2~3()~i'1 solvents at concentrations at which dissolution of the polycaprolactone or its copolymers does not take place. UseEul solvents for the selective elution of the polyether are among others aqueous solutions of methanol, ethanol, or acetone.
The formation of interconnected pores is demonstrated by the water uptake of the porous polymers. A sample o~ the porous polymer of known weight is kept submerged in water and the vessel containing the submer~ed sample is evacuated until gas evolution ceases. Then air is admitted and the sample is weighed after removal of adherent water droplets.
The fractional void content, fv~ is then calculated from fv = (wl + ~2)/W2 where wl and w2 are the weights of the sample in the dry and wet states, respectively.
Unexpectedly, it was found that the formation of interconnected pores by selective leaching of the pore-forming polyether occurs only inside a narrow temperature range of about 40~55C~ preferably about 40-45~C. More specifically, it was found that the leachin~ temperature and the composition of the eluant play a dominant role which determines the void content and the average pore dimensions of the porous tube walls. This unexpected result which assigns a lesser importance to the initial polyether content is demonstrated by the data of Table 1 which reveal that the void content of the porous polycaprolactone can considerably exceed the volume fraction of the initially present polyether. Indeed, void contents exceeding 60~ can he obtained with polycaprolactone initially containing only 5 wt-% of the polyether `'`
In ~eneral the void content increases with the content of the organic component in the aqueous eluant. There exists a critical concentration for the organic component below which the void content remains low despite all of the added polyether being eluted.
For agueous solutions of acetone this critical concentration is around 45 vol-% acetone at 40C
elution temperature and decreases to about 25 vol-%
acetone at 45C. Above the critical concentration partial melting and recrystallization of the polycaprolactone takes place during the leaching process which results in a pore structure composed of interconnected pores. Below the critical concentration the porous structure of the leached polycaprolactone changes to one of low void content and being composed of closed cells.
Table 1. Ef~ect of Leaching Conditions on the Void Content of the Walls of Porous Polycaprolactone Tubes .
Vol.-~ Percent Void Content at Acetone 40C 45C
Initial F-68 Content: 5 wt-~
5.0 5.8 6.2 15.0 15.7 35~5 45.9 59.3 66.5 75.7 Initial F-68 Content: 15 wt-%
10 6.9 9.
20 7.5 6.8 . .
'Z~330~;~
8.1 42.4 9.5 65.7 55.9 78.4 77.1 80.1 Initial F-68 Content~ 25 wt-~
6.~ 6.9 6.8 9.7 7.7 71.5 10.2 73.1 66.8 76.9 82~7 83.3 Broadly stated, the present invention provides an article suitable for use as a controlled release reservoir for high molecular weight drugs, comprising a porous polymer formed by:
~13 shaping a polylactone in the presence of a polyether; and ~2) selectively eluting said polyether at a temperature of about 40~C to 55C from sai.d ~; shaped polylactone to form interconnected pores therein.
The invention additionally provides methods for making such an article.
Brief Description of the Drawin~s The FIGURE is a graph which illustrates the cumulative release of decapeptide descrlbed in Example 1 .
3L283~
Best Mode for CarrYing Out the Invention The preparation of formulations in which the drug is contained within the cavity of the polymeric device of the present invention is a three step process. The first step involves the preparation of the tubular, non-porous, and drug-free polymeric device suitable for the subsequent pore-forming process. This is accomplished by conventional methods such as extrusion, injection molding, dip casting, or annealing of rolled films utilizing intimate blends composed of polycaprolactone or a suitable copolymer of caprolactone and proper amounts of a polyether such as Pluronic F-68. Intimate blends of polycaprolactone or its copolymers with the pore-forming polyether can also be prepared in situ by polymerizing the corresponding lactones in the presence of the polyether which has to be endcapped by acetyl groups. The amount of polyether such as Pluronic F-68 or its endcapped modification can be in the range of 5-S0~ ~w~w) but i~ preferentially between 10-25% (w~w).
During the second process step the tube walls are made porous by selectively removing the pore-forming additive in a leaching process utilizing aqueous solutions of an organic solvent such a~ methanol, ethanol, or acetone. The concentration of the organic component of the leaching bath can be in the range of lO-lO0~ (vJv). The proper selection of the concentration to be utilized depends on the kind of the organic component in the leaching solution, the temperature of the leaching path, the initial polyether eontent of the polylactone, and the desired porosity to be obtained in the final product.
330~
The leaching process must be performed at an elevated temperature between about 40 and 55~C in order to obtain porous tube walls with interconnected pores. During the leaching process the polymer tubes are supported by inserted stainless steel rods and the bath is mildly agitated. Selective elution of the pore-forming additive is generally complete after 2-3 hours when the porous tubes are cooled with ice water to facilitate crystallization. The tubes are then washed with deionized water at ambient temperature, and dried under vacuum at ambient temperature.
In the third step of the process, after fabrication of the structure, a desired drug is introduced into the cavity of such devices in a suitable form, e.g. as micronized powder or in form of a mixture with a suitable solvent, diluent, or dispersing agentO As is well documented in the public literature, and as is well known to those skilled in the art, the amount of drug, the dimensions of the polymeric device, and the amount of solvent, diluent or dispersing agent, may be varied such that th~ rate of drug delivery and the time over which the drug is delivered are considered optimum for the particular therapeutic application. The device of the present invention is in the form of a cylindrical tube with the drug contained within the interior cavity formed by the porous walls and both ends of the tubular device being closed by heat sealing.
The rate at which the polymeric device is degraded within the body is determined by the chemical structure and the molecular weight selected for the fabrication of the device as well as the mode of administration to the patient~ Polycaprolactone with an intrinsic ~13305~1L
_9 viscosity in toluene of greater than one dl/g does not begin to lose significant mechanical strength or weight for at least 12 months. A copolymer of caprolactone and dilactide with the same intrinsic viscosity is degraded within two to three months.
The following examples are offered to more fully illustrate the invention, but are not to be construed as limiting the scope thereof.
A polmer tube of 60 mm length, 2.0 mm inner diameter, and 0.15 mm wall thickness was prepared from a blend composed of 70 parts per weight of polycaprolactone with an intrinsic viscosity of 1.9 dl/g in toluene and 30 parts per weight of Pluronic F-68. After supporting the tube by an inserted stainless steel rod, the Pluronic F-68 was selectively eluted by submerging the tube in a mixture composed of one part ethanol and two parts water at 50C for 8 hours. At the end of the leaching period the tube was chilled with ice water, washed~ and then dried under vacuum at ambient temperature. From tube weight and geometric dimensions a void content of 59% was calculated.
Micrographs obtained by scanning electron microscopy revealed a very open cell structure with interconnected holes in the cell walls of about 6-8 ~m in diameter.
The pores of the wall surfaces were about 20 ~m in diameter and represented about 10% of the tube surface.
A 30 mm length of the prepared porous tube was heat sealed at one end by pressing it under rotation into a fitking conical indentation of a small Teflon block thermostated at 72C. The tube was then filled 33~5~
with 5.8 mg of a synthetic decapeptide followed by 60 mg of water. After heat sealing the tube was immersed in deionized water at 38 (and the release of the decapeptide was monitored by its absorbance at 220 nm. The decapeptide was released with a nearly constant rate of 140 ~g/day for a time period of 33 days when the device was depleted to about 20~ of its initial drug content. The release rate of the decapeptide is graph;cally depicted in the FIGURE.
In a control experiment under identical conditons but utilizing a non-porous polycaprolactone tube of identical dimensions, no release of the decapeptide could be observed during a time period of one month.
The procedure of example 1 was repeated with incorporation of the following changes. The polymer tube was prepared from a blend composed of 60 parts per weight of the polycaprolactone of example 1 and 40 parts per weight of Pluronic F-68. Selective elution of the Pluronic F-68 content was performed with a mixture of two volumes methanol and three volumes water at 50C for 16 hours. The void content of the porous tube walls was found to be 65~.
A porous polymer-drug formulation was prepared by filling a 30 mm length of the prepared porous tube with 4.6 mg of the decapeptide of example 1 and 50 mg of water. The release of the decapeptide into deionized water was monitored as in example 1 for 66 days when the drug content was completely exhausted. The maximum release rate during this time period was found to be :;.
a~o~
158 ~g/day.
A porous polymer tube wa~ prepared according to the procedure of example l but utilizing a methanol-water mixture with a volume ratio of 1:2 for the elution of the Pluronic F-68 content at 50C for lO
hours. A 27 mm length of the resulting porous tube was used for the preparation of a polymer-drug formulaton composed of 13.4 mg of an oligopeptide with a molecular weight of 5000 and 68 mg of water. The release rate of the oligopeptide into deionized water at 38C was monitored for 50 days by its abso~bance at 215 nm and was found to be in the range of 20-60 ~g/cm/day.
A porous tube was prepared according to the procedure of example l but utilizing a polymer blend composed of 80 parts per weight of polycaprolactone and 20 parts per weight of Pluronic F-68. The Pluronic F-68 content was eluted with a methanol-water mixture of a volume ratio of 2:l at 50C for l.3 hours. A porous capsule of 27 mm length was prepared which contained 20 mg of riboflavin dispersed in 60 ~l of water. The release of the riboflavin into deionized water at 38C
was monitored by its absorbance at 444 nm. During the investigated time period of 25 days a release rate of 48 ~g/cm/day was observed. In a control experiment extending over the same time period the total release of riboflavin from a non-porous polycaprolactone capsule of identical dimensions amounted to less than ,.~ lZ83 5 ~g.
The procedure of example 1 was repeated with incorporation of the following changes. The polymer tube was prepared from a blend composed of 23 parts by weight of Pluronic F-68 and 77 parts per weight of a random copolymer of E-caprolactone and ~-valerolactone containing 20 mol-~ of ester groups derived from the latter lactone. Selective elution of the Pluranic F-68 content was performed at 48C in a mixture of equal volumes of methanol and water for 8 hours. The void content of the porous tube wall was found to be 62%.
A 25 mm length of the prepared porous tube was loaded with 5.3 mg of the decapeptide of example 1 and 49 mg of water. The release rate of the decapeptide into deionized water was monitored as in example 1 for 40 days and was found to remain nearly constant at 180 ~g/day.
, A porous tube was prepared according to the procedure of example 1 by utilizing a polymer blend composed of 20 parts per weight of Pluronic F-68 and 80 parts per weight of a random copolymer of ~-caprolactone and L-dilactide containing 15 mol-% of ester groups derived from the dilactide. Selective elution of the Pluronic F-68 content at 52C in a methanol-water mixture of ratio 3:2 for 6 hours yielded a tube with porous walls ~ith a void content of 78~.
A 30 mm length of the prepared porous tube was lZ~33~5~
loaded with 6.2 m~ of the decapeptide of example l followed by 70 mg of water. The monitored release rate of the decapeptide into deionized water was found to be 230 ~g/day.
Pluronic F-68 was endcapped with acetyl groups by dissolving lO0 g F-G8 in lO0 ml freshly distilled pyridine and adding 50 ml freshly distilled acetic anhydride. After refluxing the solution for 6 hours the solvents were removed on a rotary evaporator until solidification. The solid was Soxhlet extracted with pentane for 24 hours and then vacuum dried at 40C for 24 hours.
Fifteen parts per weight of the endcapped polyether were dissolved in 85 parts per weight of caprolactone and 200 ppm of stannous octoate were added as a catalyst. The solution was kept in a sealed container at 120C for 18 hours when the conversion to polymer was better than 98~. The polymer was removed as a melt from which a film of about 0.1 mm thickness was compression molded. The intrinsic viscosity of the polymer in toluene was 0.7 dl/g.
A porous film was prepared by placing the film into an aqueous solution containing 45 vol-% acetone at 45C for 12 hours. The void content of the film as determined by its water uptake was 78~.
~.
A crosslinked polycaprolactone film was prepared by polymerizing between Teflon plates a solution composed of 85 parts per weight of caprolactone, 15 parts per weight of acetyl enclcapped Pluronic F-68 of example 7, 1 part per weight of 2,2-bis(6-hexanolacton-4-yl)propane, and 200 ppm stannous octoate. The polymerization was performed at 120C for 18 hours.
The film was made porous by placing it into an aqueous solution containing 70 vol-~ acetone at 40C
for 12 hours. The void content of the crosslinked film as determined by its water uptake was 88%.
While the invention has been described above with reference to specific examples and embodiments, it will be understood that the invention is not to be ]imited to specific examples and embodiments except as defined in the following claims.
Claims (21)
1.An article suitable for use as a controlled release reservoir for high moLecular weight drugs, comprising a porous polymer formed by (a) shaping a polylactone in the presence of a polyether; and (b) selectively eluting said polyether from said shaped polylactone at a temperature of about 40°C to 55°C to form interconnected pores therein.
2. The article of claim 1 wherein said polyether is endcapped with acetyl groups.
3. The article of claim 1 wherein the endcapped polyether of claim 2 is added to the monomeric lactone prior to the polymerization.
4. The article of claim 1 wherein, prior to said selective elution step, said polyether is present in an amount of 5-50% based on the weight of said blend.
5. The article of claim 4 wherein said polyether is present in an amount of 10-30% based on the weight of said blend.
6. The article of claim 1, wherein said polylactone is polycaprolactone.
7. The article of claim 1, wherein said polylactone is a copolymer formed from caprolactone and at least one other lactone or bis-lactone.
8. The article of claim 1, wherein said shaped polylactone is in the form of a tube.
9. The article of claim 1, wherein said polyether is eluted from said shaped polylactone with aqueous solutions of an organic solvent.
10. The article of claim 9, wherein said organic solvent is acetone present in an amount of 20-70%.
11. The article of claim 9, wherein said organic solvent is methanol or ethanol present in an amount of 20-50%.
12. A method of fabricating a porous shaped article suitable for use as a controlled release reservoir for high molecular weight drugs, comprising (a) shaping a blend of polylactone and a polyether to form a shaped article; and (b) selectively eluting said polyether from said shaped article to form interconnected pores therein.
13. The method of claim 12 wherein said polyether is endcapped with acetyl groups and is added to the monomeric lactone prior to the polymerization.
14. The method of claim 12, wherein prior to said selective elution step, said polyether is present in an amount of 5-50% based on the weight of said blend.
15. The method of claim 14, wherein said polyether is present in an amount of 20-30% based on the weight of said blend.
16 16. The method of claim 12, wherein said polylactone is polycaprolactone.
17. The method of claim 12, wherein said polylactone is a copolymer formed from caprolactone and at least one other lactone or bis-lactone.
18. The method of claim 12, wherein said shaped polylactone is in the form of a tube.
19. The method of claim 12, wherein said polyether is selectively eluted with aqueous solutions of an organic solvent.
20. The method of claim 19, wherein said organic solvent is acetone present in an amount of 20-70%.
21. The method of claim 19, wherein said organic solvent is methanol or ethanol present in an amount of 20-50%.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US798,883 | 1985-11-18 | ||
| US06/798,883 US4702917A (en) | 1985-11-18 | 1985-11-18 | Porous bioabsorbable polyesters |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1283051C true CA1283051C (en) | 1991-04-16 |
Family
ID=25174507
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000523151A Expired - Fee Related CA1283051C (en) | 1985-11-18 | 1986-11-17 | Porous bioabsorbable polyesters |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US4702917A (en) |
| EP (1) | EP0223708B1 (en) |
| JP (1) | JPS62164743A (en) |
| KR (1) | KR870004698A (en) |
| AT (1) | ATE65911T1 (en) |
| AU (1) | AU599612B2 (en) |
| CA (1) | CA1283051C (en) |
| DE (1) | DE3680754D1 (en) |
| DK (1) | DK549486A (en) |
| NO (1) | NO864507L (en) |
Families Citing this family (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0183103B1 (en) * | 1984-11-09 | 1988-08-03 | TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION | Flat permeable membrane and method for manufacture thereof |
| CA1312429C (en) * | 1985-08-29 | 1993-01-12 | Yukio Seita | Porous membrane for separation of blood components and method for manufacture thereof |
| SE8802414D0 (en) * | 1988-06-27 | 1988-06-28 | Astra Meditec Ab | NEW SURGICAL MATERIAL |
| US4961707A (en) * | 1987-12-22 | 1990-10-09 | University Of Florida | Guided periodontal tissue regeneration |
| US5641505A (en) * | 1988-06-27 | 1997-06-24 | Astra Tech Aktiebolag | Porous flexible sheet for tissue separation |
| US5843156A (en) | 1988-08-24 | 1998-12-01 | Endoluminal Therapeutics, Inc. | Local polymeric gel cellular therapy |
| US5575815A (en) * | 1988-08-24 | 1996-11-19 | Endoluminal Therapeutics, Inc. | Local polymeric gel therapy |
| US5213580A (en) * | 1988-08-24 | 1993-05-25 | Endoluminal Therapeutics, Inc. | Biodegradable polymeric endoluminal sealing process |
| DE68922497T2 (en) * | 1988-08-24 | 1995-09-14 | Marvin J Slepian | ENDOLUMINAL SEAL WITH BISDEGRADABLE POLYMERS. |
| US5634946A (en) * | 1988-08-24 | 1997-06-03 | Focal, Inc. | Polymeric endoluminal paving process |
| US5328471A (en) | 1990-02-26 | 1994-07-12 | Endoluminal Therapeutics, Inc. | Method and apparatus for treatment of focal disease in hollow tubular organs and other tissue lumens |
| US4938763B1 (en) * | 1988-10-03 | 1995-07-04 | Atrix Lab Inc | Biodegradable in-situ forming implants and method of producing the same |
| US5700479A (en) * | 1988-12-23 | 1997-12-23 | Guidor Ab | Surgical element and method for selective tissue regeneration |
| US5610214A (en) * | 1988-12-29 | 1997-03-11 | Deknatel Technology Corporation, Inc. | Method for increasing the rate of absorption of polycaprolactone |
| US5487897A (en) * | 1989-07-24 | 1996-01-30 | Atrix Laboratories, Inc. | Biodegradable implant precursor |
| USRE37950E1 (en) | 1990-04-24 | 2002-12-31 | Atrix Laboratories | Biogradable in-situ forming implants and methods of producing the same |
| ATE125446T1 (en) * | 1990-05-01 | 1995-08-15 | Res Triangle Inst | BIODEGRADABLE POLYESTERS FOR DELAYED MEDICINAL RELEASE. |
| CA2064410A1 (en) * | 1991-04-01 | 1992-10-02 | Masanobu Ajioka | Degradable foam and use of same |
| US5238968A (en) * | 1991-04-24 | 1993-08-24 | Mitsui Toatsu Chemicals, Inc. | Process for preparing a degradable high polymer network |
| US5223546A (en) * | 1991-04-24 | 1993-06-29 | Mitsui Toatsu Chemicals, Inc. | High polymer network |
| US5271736A (en) * | 1991-05-13 | 1993-12-21 | Applied Medical Research | Collagen disruptive morphology for implants |
| HUT67238A (en) * | 1991-05-14 | 1995-03-28 | Endocon Inc | Controlled realising implant preparations |
| US5330768A (en) * | 1991-07-05 | 1994-07-19 | Massachusetts Institute Of Technology | Controlled drug delivery using polymer/pluronic blends |
| CH684273A5 (en) * | 1992-02-25 | 1994-08-15 | Weidmann H Ag | Porous dimensionally stable body. |
| WO1993022987A2 (en) * | 1992-05-20 | 1993-11-25 | Cytrx Corporation | Gel composition for implant and method |
| DE4239781A1 (en) * | 1992-11-26 | 1994-06-01 | Basf Ag | Molded articles made of foamed polylactides and process for their production |
| DE69414558T2 (en) * | 1993-03-23 | 1999-07-15 | Focal Inc | DEVICE AND METHOD FOR LOCAL APPLICATION OF POLYMER MATERIAL ON FABRIC |
| US6004547A (en) | 1997-09-29 | 1999-12-21 | Focal, Inc. | Apparatus and method for local application of polymeric material to tissue |
| US5849035A (en) * | 1993-04-28 | 1998-12-15 | Focal, Inc. | Methods for intraluminal photothermoforming |
| US5542594A (en) * | 1993-10-06 | 1996-08-06 | United States Surgical Corporation | Surgical stapling apparatus with biocompatible surgical fabric |
| US5502092A (en) * | 1994-02-18 | 1996-03-26 | Minnesota Mining And Manufacturing Company | Biocompatible porous matrix of bioabsorbable material |
| US5607686A (en) * | 1994-11-22 | 1997-03-04 | United States Surgical Corporation | Polymeric composition |
| US5641502A (en) * | 1995-06-07 | 1997-06-24 | United States Surgical Corporation | Biodegradable moldable surgical material |
| US5736152A (en) * | 1995-10-27 | 1998-04-07 | Atrix Laboratories, Inc. | Non-polymeric sustained release delivery system |
| US5861174A (en) | 1996-07-12 | 1999-01-19 | University Technology Corporation | Temperature sensitive gel for sustained delivery of protein drugs |
| AU5596898A (en) * | 1996-12-03 | 1998-06-29 | Osteobiologics, Inc. | Biodegradable polymeric film |
| US6186985B1 (en) * | 1997-10-03 | 2001-02-13 | Boston Scientific Corporation | Gastro-intestinal tube with dissolvable support bolster |
| US7128927B1 (en) | 1998-04-14 | 2006-10-31 | Qlt Usa, Inc. | Emulsions for in-situ delivery systems |
| US6261583B1 (en) * | 1998-07-28 | 2001-07-17 | Atrix Laboratories, Inc. | Moldable solid delivery system |
| US6143314A (en) * | 1998-10-28 | 2000-11-07 | Atrix Laboratories, Inc. | Controlled release liquid delivery compositions with low initial drug burst |
| US6110484A (en) | 1998-11-24 | 2000-08-29 | Cohesion Technologies, Inc. | Collagen-polymer matrices with differential biodegradability |
| US6325810B1 (en) | 1999-06-30 | 2001-12-04 | Ethicon, Inc. | Foam buttress for stapling apparatus |
| US8226598B2 (en) | 1999-09-24 | 2012-07-24 | Tolmar Therapeutics, Inc. | Coupling syringe system and methods for obtaining a mixed composition |
| US6273897B1 (en) | 2000-02-29 | 2001-08-14 | Ethicon, Inc. | Surgical bettress and surgical stapling apparatus |
| US6758857B2 (en) | 2000-11-13 | 2004-07-06 | Acmi Corporation | Treatment catheters with thermally insulated regions |
| US20030185973A1 (en) * | 2002-03-30 | 2003-10-02 | Crawley Richard L. | Water vapor plasma method of increasing the surface energy of a surface |
| US7393339B2 (en) | 2003-02-21 | 2008-07-01 | C. R. Bard, Inc. | Multi-lumen catheter with separate distal tips |
| WO2004087797A1 (en) * | 2003-04-03 | 2004-10-14 | Corporation De L'ecole Polytechnique De Montreal | Microporous articles comprising biodegradable medical polymers, method of preparation thereof and method of use thereof |
| US20040243095A1 (en) | 2003-05-27 | 2004-12-02 | Shekhar Nimkar | Methods and apparatus for inserting multi-lumen spit-tip catheters into a blood vessel |
| US20050266043A1 (en) * | 2004-05-27 | 2005-12-01 | Medtronic Vascular, Inc. | Methods and compounds for treatment of aneurysmal tissue |
| US8992454B2 (en) | 2004-06-09 | 2015-03-31 | Bard Access Systems, Inc. | Splitable tip catheter with bioresorbable adhesive |
| US20050283111A1 (en) * | 2004-06-22 | 2005-12-22 | Dan Maurice | Catheter assembly with degradable material |
| JP5098443B2 (en) * | 2007-05-31 | 2012-12-12 | 東レ株式会社 | Polylactic acid separation membrane and method for producing the same |
| US8500939B2 (en) | 2007-10-17 | 2013-08-06 | Bard Access Systems, Inc. | Manufacture of split tip catheters |
| US8066660B2 (en) | 2007-10-26 | 2011-11-29 | C. R. Bard, Inc. | Split-tip catheter including lateral distal openings |
| US8292841B2 (en) | 2007-10-26 | 2012-10-23 | C. R. Bard, Inc. | Solid-body catheter including lateral distal openings |
| US9579485B2 (en) | 2007-11-01 | 2017-02-28 | C. R. Bard, Inc. | Catheter assembly including a multi-lumen configuration |
| WO2009059220A1 (en) | 2007-11-01 | 2009-05-07 | C.R. Bard, Inc. | Catheter assembly including triple lumen tip |
| US8858995B2 (en) | 2008-03-10 | 2014-10-14 | University Of Louisville Research Foundation, Inc. | Methods and compositions for controlled delivery of phytochemical agents |
| WO2009114525A1 (en) * | 2008-03-10 | 2009-09-17 | University Of Louisville Research Foundation, Inc. | Methods and compositions for controlled delivery of phytochemical agents |
| USD748252S1 (en) | 2013-02-08 | 2016-01-26 | C. R. Bard, Inc. | Multi-lumen catheter tip |
| US10258768B2 (en) | 2014-07-14 | 2019-04-16 | C. R. Bard, Inc. | Apparatuses, systems, and methods for inserting catheters having enhanced stiffening and guiding features |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2894289A (en) * | 1956-03-01 | 1959-07-14 | Dow Chemical Co | Method of making permeselective membranes |
| US3423491A (en) * | 1964-09-02 | 1969-01-21 | Dow Chemical Co | Permselective hollow fibers and method of making |
| US3887699A (en) * | 1969-03-24 | 1975-06-03 | Seymour Yolles | Biodegradable polymeric article for dispensing drugs |
| GB1412983A (en) * | 1971-11-30 | 1975-11-05 | Debell & Richardson | Method of producing porous plastic materials |
| US4148871A (en) * | 1977-10-11 | 1979-04-10 | Pitt Colin G | Sustained subdermal delivery ofdrugs using poly(ε-caprolactone) and its copolymers |
-
1985
- 1985-11-18 US US06/798,883 patent/US4702917A/en not_active Expired - Fee Related
-
1986
- 1986-11-12 NO NO864507A patent/NO864507L/en unknown
- 1986-11-13 AT AT86402527T patent/ATE65911T1/en not_active IP Right Cessation
- 1986-11-13 EP EP86402527A patent/EP0223708B1/en not_active Expired - Lifetime
- 1986-11-13 DE DE8686402527T patent/DE3680754D1/en not_active Expired - Fee Related
- 1986-11-13 JP JP61270834A patent/JPS62164743A/en active Pending
- 1986-11-14 AU AU65159/86A patent/AU599612B2/en not_active Ceased
- 1986-11-17 DK DK549486A patent/DK549486A/en not_active Application Discontinuation
- 1986-11-17 KR KR860009685A patent/KR870004698A/en not_active Application Discontinuation
- 1986-11-17 CA CA000523151A patent/CA1283051C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP0223708A2 (en) | 1987-05-27 |
| NO864507L (en) | 1987-05-19 |
| AU599612B2 (en) | 1990-07-26 |
| NO864507D0 (en) | 1986-11-12 |
| EP0223708A3 (en) | 1988-01-13 |
| DE3680754D1 (en) | 1991-09-12 |
| AU6515986A (en) | 1987-05-21 |
| ATE65911T1 (en) | 1991-08-15 |
| DK549486D0 (en) | 1986-11-17 |
| JPS62164743A (en) | 1987-07-21 |
| EP0223708B1 (en) | 1991-08-07 |
| KR870004698A (en) | 1987-06-01 |
| DK549486A (en) | 1987-05-19 |
| US4702917A (en) | 1987-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1283051C (en) | Porous bioabsorbable polyesters | |
| Mathiowitz et al. | Polyanhydride microspheres as drug carriers I. Hot-melt microencapsulation | |
| Grizzi et al. | Hydrolytic degradation of devices based on poly (DL-lactic acid) size-dependence | |
| US4450150A (en) | Biodegradable, implantable drug delivery depots, and method for preparing and using the same | |
| Bodmeier et al. | The preparation and evaluation of drug-containing poly (dl-lactide) microspheres formed by the solvent evaporation method | |
| Hsu et al. | Effect of polymer foam morphology and density on kinetics of in vitro controlled release of isoniazid from compressed foam matrices | |
| Sato et al. | Porous biodegradable microspheres for controlled drug delivery. I. Assessment of processing conditions and solvent removal techniques | |
| US4720384A (en) | Manufacture of hollow fine tubular drug delivery systems | |
| US4882168A (en) | Polyesters containing alkylene oxide blocks as drug delivery systems | |
| EP0258780B1 (en) | Polyesters containing alkylene oxide blocks as drug delivery systems | |
| US4673565A (en) | Pharmaceutical compositions containing hollow fine tubular drug delivery systems | |
| CA2038040A1 (en) | Process for preparing foamed bioabsorbable polymer particles | |
| US20070098757A1 (en) | E-PTFE foil impregnated with an encapsulated bioactive substance | |
| Domb et al. | Preparation and characterization of carmustine loaded polyanhydride wafers for treating brain tumors | |
| WO1996025148A1 (en) | A time-release delivery matrix composition and corresponding controlled-release compositions | |
| Van de Witte et al. | Formation of porous membranes for drug delivery systems | |
| US4645664A (en) | Microporous powder form polylactides | |
| US5352455A (en) | Controlled release compositions | |
| Shieh et al. | Drug release from a new family of biodegradable polyanhydrides | |
| Turczyn et al. | In situ self hardening bioactive composite for bone and dental surgery | |
| WO1989005138A1 (en) | Method of forming bioerodible implants for improved controlled drug release | |
| Kishida et al. | Some determinants of morphology and release rate from poly (L) lactic acid microspheres | |
| Marcotte et al. | Delayed release of water-soluble macromolecules from polylactide pellets | |
| Khamlao et al. | Preparation of self-solidifying polymeric depots from PLEC-PEG-PLEC triblock copolymers as an injectable drug delivery system | |
| EP0391852A2 (en) | Pharmaceutical compositions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKLA | Lapsed |